JMP Securities Downgrades Cadence Pharmaceuticals (CADX) to Underperform
CADX Hot Sheet
Rating Summary:6 Buy, 2 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
JMP Securities downgrades Cadence Pharmaceuticals (Nasdaq: CADX) from Market Perform to Underperform.
To see more analyst ratings on CADX Click Here.
Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada.
To see more analyst ratings on CADX Click Here.
Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Barclays Cuts Estimates and Price Target on ADP (ADP); Mixed Data From Investor Day
- UBS Maintains a 'Buy' on Teva Pharma (TEVA); CEO Highlights From Conference Call
Create E-mail Alert Related Categories
DowngradesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
